Drug resistant tumours

Bennis, S. Chapey, C. Couvreur, R Robert, J. Enhanced cytotoxicity of doxorubicin encapsulated in polyhexylcyanoacrylate nanospheres against multi-drug-resistant tumour cells in culture. Eur. J. Cancer 1994, 30A, 89-93. 

BLOCK COPOLYMER-BASED FORMULATIONS OF DOXORUBICIN EFFECTIVE AGAINST DRUG RESISTANT TUMOURS... 

Selective Effect of Copolymers on Cytotoxic Activity of Doxorubicin against Drug Resistant Tumour Cells... 

The combination of the two aforementioned properties of Pluronic block copolymers, i.e. tbeir flexibility in pharmaceutical formulations and their ability to produce strong and selective effects on drug resistant tumour cells, has suggested that clinically effective anticancer formulations may be developed on their basis. 

To assess the mechanism by which Pluronic copolymers hypersensitise drug resistant tumour cells, we have analysed the effect of these compounds on the drug transport into and within the cells, as well as the drug interaction with DNA, which is known to be the target for cytotoxic activity of doxorubicin. ... 

Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ (1995) The drug resistance-relateid protein LRP is Ae human major vault protein. Nat Med 1 578-582 Schiemann U, Assert R. Moskopp D, Gellner R, Hengst K, Gullotta F, Domschke W, Pfeiffer A (1997) Analysis of a protein kinase C-alpha mutation in human pituitary tumours. ] Endocrinol 153 131-137... 

FU has been extensively used in the treatment of skin cancers and a variety of solid tumours, such as breast, colorectal and gastric cancers, usually via intravenous (i.v.) administration. Although this route is generally the most efficient and the least toxic, it is costly and inconvenient [87], Furthermore, treatment of cancer with 5-FU has been found to cause neurotoxic and cardiotoxic side effects. Toxicity also derives from the lack of selectivity of the drug towards tumours, and resistance can occur if the cell produces excess of dump, for competing with the drug in the active site [88]. 

J. A. Plumb, R. Milroy, and S, B. Kaye, The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereo-specific, Btocfiem. Pfiarmacoi., 39 787-792 (1990). 

---